Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.

被引：5

作者：

Argiris, Athanassios

Li, Shuli

Savvides, Panayiotis

Ohr, James

Gilbert, Jill

Levine, Marshall A.

Haigentz, Missak

Saba, Nabil F.

Chakravarti, Arnab

Ikpeazu, Chukwuemeka

Schneider, Charles

Pinto, Harlan

Forastiere, Arlene A.

Burtness, Barbara

机构：

[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Dign Hlth St Josephs Hosp, Phoenix, AZ USA

[4] Univ Pittsburgh, Med Ctr, Canc Ctr Pavilion, Pittsburgh, PA USA

[5] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[6] Greater Baltimore Med Ctr, Towson, MD USA

[7] Albert Einstein Coll Med, Bronx, NY 10467 USA

[8] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA

[9] Winship Canc Inst, Atlanta, GA USA

[10] Ohio State Univ, Columbus, OH 43210 USA

[11] Univ Miami, Sylvester Comprehens Canc Ctr, Plantation, FL USA

[12] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA

[13] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[14] VA Palo Alto, Palo Alto, CA USA

[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[16] Yale Sch Med, New Haven, CT USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.6000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6000

引用

页数：4